Li Chen

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

Qin Xu, Junjie Wang, Yang Sun et al. · Journal of Clinical Oncology · 2022 · 145 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Song‐Yang Wu, Ying Xu, Li Chen et al. · Molecular Cancer · 2022 · 97 citations · Full text

Life Sciences, Immunology, Oncology +17

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Li Chen, Yi‐Zhou Jiang, Song‐Yang Wu et al. · Clinical Cancer Research · 2022 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17

Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial

Lei Fan, Zhonghua Wang, Linxiaoxi Ma et al. · The Lancet Oncology · 2024 · 64 citations

Medicine, Oncology, Breast Oncology +8

CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas

J. Robert Kane, Junfei Zhao, Takashi Tsujiuchi et al. · Clinical Cancer Research · 2020 · 36 citations · Full text

Medicine, Immunology, Oncology +17